Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash & Current Investments (2020 - 2023)

Cullinan Therapeutics has reported Cash & Current Investments over the past 4 years, most recently at $466.4 million for Q3 2023.

  • Quarterly results put Cash & Current Investments at $466.4 million for Q3 2023, down 19.02% from a year ago — trailing twelve months through Sep 2023 was $466.4 million (down 19.02% YoY), and the annual figure for FY2022 was $467.3 million, up 60.88%.
  • Cash & Current Investments for Q3 2023 was $466.4 million at Cullinan Therapeutics, down from $841.8 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for CGEM hit a ceiling of $841.8 million in Q2 2023 and a floor of $210.2 million in Q4 2020.
  • Median Cash & Current Investments over the past 4 years was $466.9 million (2022), compared with a mean of $488.6 million.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 81.46% in 2022 and later fell 29.43% in 2023.
  • Cullinan Therapeutics' Cash & Current Investments stood at $210.2 million in 2020, then skyrocketed by 38.18% to $290.5 million in 2021, then soared by 60.88% to $467.3 million in 2022, then decreased by 0.18% to $466.4 million in 2023.
  • The last three reported values for Cash & Current Investments were $466.4 million (Q3 2023), $841.8 million (Q2 2023), and $390.7 million (Q1 2023) per Business Quant data.